TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dose Confirmation Efficacy Study (V260-007)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants~Exclusion Criteria:~* History of abdominal disorders from a birth defect, intussusception, or abdominal surgery~* Known or suspected problems with immune system~* Fever at time of immunization~* Prior administration of a rotavirus vaccine~* History of known prior rotavirus disease~* Chronic diarrhea, or failure to thrive

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose) (Type: EXPERIMENTAL): Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent)~administered 28 to 70 days apart.
- Placebo matching RotaTeq™ (Type: PLACEBO_COMPARATOR): Placebo matching RotaTeq™ administered 28 to 70 days apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Auriculotherapy as a Coping Strategy in Professional Nursing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Average and high score by the List of Stress Symptoms~* Voluntary participation in the study~* Availability of time for submission to the sessions~Exclusion Criteria:~* Pregnancy~* Medical license or vacation during the period~* Low score of stress

- Gender: ALL
- Minimum Age: 23 Years
- Maximum Age: 61 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
- Auriculotherapy by needles (Type: EXPERIMENTAL): The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
- Auriculotherapy by seeds (Type: EXPERIMENTAL): The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Oligofructose on Appetite in Overweight Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females aged 20-50~* BMI 25-35 kg/m2~* Weight stable for three months prior to enrollment in study (weight change \< 3 kg over a period of three months)~* Habitual dietary fibre ≤ 25g/day (as assessed by 3-day dietary record)~* Non-smokers~* No current or history of endocrine disease, gastrointestinal disease, kidney or liver diseases, cardiovascular disease, pancreatitis, or cancer~* Hydrogen producers~Exclusion Criteria:~* Use of antibiotic less than three months prior to participation in the study~* Participation in other research studies in the previous three months~* Blood donation less than three months before participation in study~* Anaemia~* Hypertension~* Pregnancy or breastfeeding~* Substance abuse~* Vegan diet~* Regular use of prebiotic, probiotic or symbiotic food items/ supplements~* Intense exercise undertaken for more than 5h per week~* Metallic or electronic implants e.g. pacemaker, cochlear ear implants, fixed dental braces~* Claustrophobia~* Depression

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Oligofructose (Type: EXPERIMENTAL): Participants received 10g of Oligofructose powdered supplements in sachets each containing 10 g dietary fiber) three times per day. Volunteers were instructed to take the supplement with their main meals.The 8-week supplementation period took place between visits 3 and 4 and included a 2-week run-in period to allow the bowel to adapt to the 30 g of dietary fiber.
- Cellulose and maltodextrin (Type: PLACEBO_COMPARATOR): Participants received 10g of Cellulose powdered supplements in sachets each containing 10 g dietary fiber) three times per day. Volunteers were instructed to take the supplement with their main meals. Maltodextrin was added to the cellulose supplement. The 8-week supplementation period took place between visits 3 and 4 and included a 2-week run-in period to allow the bowel to adapt to the 30 g of dietary fiber.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Inoperable metastatic or locally advanced breast cancer~2. No more than 2 prior chemotherapy regimens given in a metastatic or locally advanced setting and prior treatment in the metastatic setting must have included a taxane~Exclusion Criteria:~1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to Day 1 of Cycle 1~2. Patients who have had any major surgery within 4 weeks prior to Day 1 of Cycle or minor surgery within 2 weeks prior to Day 1 of Cycle 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NKTR-102 q14d (Type: EXPERIMENTAL): NKTR-102
- NKTR-102 q21d (Type: EXPERIMENTAL): NKTR-102

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A morphologically proven diagnosis of AML according to the WHO classification~* Serum creatinine \< 2N; AST and ALT \< 2.5N; total bilirubin \< 2N (unless related to the underlying disease).~* ECOG performance status 0 to 2.~* Women of child-bearing must use acceptable contraceptive methods, and must have a negative serum or urine pregnancy test within 2 weeks prior the beginning treatment on this trial.~* Must be able and willing to give written informed consent~Exclusion Criteria:~* Patients with M3-AML. Patient with AML following diagnosed myeloproliferation or patient with prior history of MDS known for more than 3 months. Patients with AML secondary to previous treatment with cytotoxic chemotherapy or radiotherapy (therapy-related AML).~* Patient presenting any diagnosis of uncontrolled or metastatic tumor.~* Patients with uncontrolled severe infection,

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- EMA+GM-CSF (Type: EXPERIMENTAL): * Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~* AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~* Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~* AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10.~* GM-CSF (LeucomaxR): 5 µg/kg/jour IV over 6 hours from day 1 to day 10.
- EMA without GM-CSF (Type: ACTIVE_COMPARATOR): * Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~* AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~* Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~* AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10.
- HD AraC+ GM-CSF (Type: EXPERIMENTAL): * AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5~* GM-CSF :5 µg/kg/d IV (6 hours) from day1 to day 5
- HD-AraC without GM-CSF (Type: ACTIVE_COMPARATOR): - AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Healthy volunteers:~1. Male or female between 18 and 55 years old with a BMI of 18-34 kg/m2 with a minimum body weight of 45 kg~2. Must be in good health and not have any health condition which could interfere with the absorption, distribution or elimination of study drug, or with the clinical and laboratory assessments in this study~Chronic HBV patients:~Key Inclusion Criteria:~1. Male or female ≥ 18 and ≤ 65 years of age.~2. In good general health except for chronic HBV infection, documented by:~   1. Clinical history, physical exam and routine laboratory measurements without major or clinically significant findings~  2. Serologic profile consistent with chronic HBV infection • HBeAg-positive at Screening with HBV viral load ≥ 2× 105 IU/mL~3. Liver evaluation demonstrating the absence of bridging fibrosis or cirrhosis~Key Exclusion Criteria:~1. History or evidence of decompensated liver disease at any time prior to Screening~2. History or presence of any other clinically significant current medical conditions requiring ongoing pharmacological treatment.~3. Previous treatment with any investigational HBV antiviral treatments within the last 6 months, or previous treatment at any time with an investigational HBV antiviral treatment of the same class (core protein targeted therapies).~4. Previous treatment with a commercially approved HBV therapy within the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- ABI-H2158 (Type: EXPERIMENTAL): ABI-H2158 in varying doses of tablets by mouth without and with food for 1 day or 10 days
- Matching Placebo for ABI-H2158 (Type: PLACEBO_COMPARATOR): Matching Placebo in varying doses of tablets by mouth without and with food for 1 day or 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-Market Surveillance With a Novel mHealth Platform

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>18~* English-speaking~* Planned for either a bariatric surgical procedure (either sleeve gastrectomy or gastric bypass) or catheter-based atrial fibrillation ablation~* Participant is willing and able to read and sign consent and participate in study~* Participant has an email account and a mobile device (smartphone or tablet) able to download the necessary applications~* Participant is willing to use the mobile health platform and syncable devices (e.g. Fitbit Charge 2)~* Attending bariatric surgeon or electrophysiologist (as appropriate) concurs that patient is a candidate for enrollment~Exclusion Criteria:~Healthy patients~Patients who refuse participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Data from a mHealth platform after bariatric surgery (Type: None): Patients that have undergone sleeve gastrectomy or gastric bypass will pilot test the use of the patient-led, smartphone based, mhHealth platform HUGO.
- Data from a mobile health platform after atrial fibrillation (Type: None): Patients that have undergone a catheter-based atrial fibrillation ablation will pilot test the use of the patient-led, smartphone based, mobile health platform HUGO.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women age ≥20 years old~* Diagnosed with Type 2 diabetes mellitus at least 3 months before run-in period~* HbA1c of ≥7.0% and ≤10.0%~Exclusion Criteria:~* Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus~* Past or current history of severe diabetic complications~* Fasting plasma glucose \> 270 mg/dL before treatment start~* History of hereditary glucose-galactose malabsorption or primary renal glucosuria~* Patients requiring insulin therapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TA-7284 Low (Type: EXPERIMENTAL): None
- TA-7284 High (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Therapeutic Effect of Different Doses of Capecitabine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* According to the diagnostic criteria for colon cancer in the Consensus on Screening, Diagnosis and Treatment of Early Colorectal Cancer and Precancerous Lesions in China , colon cancer was confirmed by pathology~* TNM(tumor node metastasis) clinical stage was III or IV~* Predicted survival period \> 3 months~Exclusion Criteria:~* Patients with heart, liver, kidney and other important organ failure and contraindications to chemotherapy~* Patients who received other anti-tumor therapy before admission~* The disease progressed rapidly and could not be successfully completed by this researcher~* Allergic to related drugs

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- the control group: a total daily dose of 2,500 mg/m2 (Type: EXPERIMENTAL): The control group was treated with capecitabine at a conventional dose: 1,250 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 2,500 mg/m2). Treatment was given for 2 weeks, followed by a 1 week of discontinuation, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.
- the medium-dose group: a total daily dose of 2,000 mg/m2 (Type: ACTIVE_COMPARATOR): The medium-dose group was treated with medium-dose capecitabine: 1,000 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 2,000 mg/m2). Treatment was given for 2 weeks, followed by a 1 week of discontinuation, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.
- the low-dose group: a total daily dose of 1,500 mg/m2 (Type: ACTIVE_COMPARATOR): The low-dose group was treated with low-dose capecitabine: 750 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 1,500 mg/m2). Treatment was given for 3 weeks per cycle, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject has completed Baxter protocol 069901~* Subject is HIV-1 seronegative or, if HIV-1 seropositive, has a CD4+ lymphocyte count \>= 400/mm3 documented within three months of the screening visit~* Subject (and his legally acceptable representative, in the case of study participants \>= 10 and \< 18 years of age) has been informed of the nature of the study, agreed to its provisions, and signed and dated the informed consent form approved by the appropriate IRB/IEC and Baxter~Exclusion Criteria:~* The subject received factor VIII products other than rAHF-PFM upon completion of Baxter protocol 069901~* The subject developed an inhibitor to factor VIII, measured in the central laboratory, during Baxter protocol 069901. An inhibitor is defined as a Bethesda titer \> 1.0 or, if Bethesda titer \< 1.0, confirmation using the Nijmegen modification of the Bethesda assay with a titer \> 0.6~* The subject is scheduled to receive an immunomodulating drug other than anti-retroviral chemotherapy (e.g., a-interferon, steroids) during the course of the study~* The subject is identified by the investigator as being unable or unwilling to cooperate with study procedures

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Contact Lens Discomfort With Orthokeratology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A completed comprehensive eye exam within the past two years~* Contact lens discomfort or discontinuation of contact lenses because of discomfort within the past 6 months~* Able to wear the Emerald™ Contact Lens (Oprifocon A, Euclid Systems Corporation)~* Refractive error better than -5.00 diopters with less than 1.50 diopters of cylinder~* Keratometry values between 40.00 D and 46.00 D~Exclusion Criteria:~* Past orthokeratology use~* Ocular surgery within the past 12 months~* History of severe ocular trauma~* Active ocular infection or inflammation~* Ocular disease other than dry eye~* Accutane or ocular medication use~* Pregnant or breast feeding~* A condition or situation that may put the subject at significant risk, confound the study results, or may significantly interfere with study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Orthokeratology Group (Type: EXPERIMENTAL): All subjects will be fit in orthokeratology contact lenses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Disseminating a Model Intervention to Promote Improved Attention-deficit Hyperactivity Disorder (ADHD) Care in the Community

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pediatric practice with at least 2 physicians~Exclusion Criteria:~* no electronic billing system

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Wait-list control (Type: NO_INTERVENTION): Wait-list control group
- ADHD Collaborative Intervention (Type: EXPERIMENTAL): This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a Diagnostic and Statistical Manual-IV (DSM-IV) based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales. The intervention lasts for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronological age ≥ 3 and chronological or bone age less than or equal to 11 years inclusive in girls;~* Chronological age ≥ 3 and chronological or bone age less than or equal to 12 years inclusive for boys~* Prepubertal~* Height SD score of \< -2~* IGF-1 SD score of \< -2~Exclusion Criteria:~* Prior treatment with rhGH, rhIGF-1, or other growth-influencing medications~* Growth failure associated with other identifiable causes (e.g., syndromes, chromosomal abnormality)~* Chronic illness such as diabetes, cystic fibrosis, etc.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Untreated (Type: NO_INTERVENTION): Observational Group
- 40 μg/kg BID (twice daily dosing) (Type: EXPERIMENTAL): Injection of rhIGF-1 40 μg/kg BID. Per protocol amendment these subjects were reassigned to receive 120 μg/kg BID. Due to the dose change, the efficacy results for these subjects were analysed in a separate subanalysis. For all outcome measures, mean and standard deviations were not calculated for this arm.
- 80 μg/kg BID (twice daily dosing) (Type: EXPERIMENTAL): Injection of rhIGF-1 80 μg/kg BID
- 120 μg/kg BID (twice daily dosing) (Type: EXPERIMENTAL): Injection of rhIGF-1 120 μg/kg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete